Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) is set to announce its earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of C($0.21) per share for the quarter.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last released its quarterly earnings data on Tuesday, March 19th. The company reported C($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.19) by C($0.04). The business had revenue of C$0.04 million for the quarter, compared to the consensus estimate of C$0.09 million.
AUP stock opened at C$8.25 on Friday. Aurinia Pharmaceuticals has a twelve month low of C$6.61 and a twelve month high of C$10.47. The company has a market cap of $770.43 million and a price-to-earnings ratio of -10.91.
In related news, Senior Officer Neil Solomons sold 34,733 shares of Aurinia Pharmaceuticals stock in a transaction on Thursday, April 25th. The shares were sold at an average price of C$8.44, for a total value of C$293,285.45. Following the transaction, the insider now directly owns 253,266 shares in the company, valued at approximately C$2,138,578.10.
A number of analysts have weighed in on AUP shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, March 20th. Svb Leerink reissued an “outperform” rating on shares of Aurinia Pharmaceuticals in a report on Tuesday, March 19th.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: Strangles
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.